Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de vismia

Cosmetic or pharmaceutical and particularly dermatological composition containing a vismia extract

Abstract

A Vismia extract, particularly a Vismia cayennensis extract, is used to prepare a cosmetic or pharmaceutical and particularly dermatological composition. The Vismia extract promotes collagen synthesis, in particular for controlling sking ageing or enhancing skin firmness.
L'invention concerne l'utilisation d'extrait de Vismia. Un extrait de Vismia, en particulier de Vismia cayennensis, est utilisé pour la préparation d'une composition cosmétique ou pharmaceutique, notamment dermatologique. L'extrait de Vismia permet de favoriser la synthèse du collagène, notamment pour lutter contre les effets du vieillissement cutané ou pour favoriser le raffermissement cutané.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (3)

    Title
    B. BOTTA ET AL.: "VISMIONE H AND PRENYLATED XANTHONES FROM VISMIA GUINEENSIS", PHYTOCHEMISTRY, vol. 25, no. 5, 1986, pages 1217 - 1219
    R. E. SCHULTES: "DE PLANTIS TOXICARIIS E MUNDO NOVO TROPICALE COMMENTATIONES XXX", BOTANICAL MUSEUM LEAFLETS, vol. 29, no. 1, 1983, pages 49 - 57
    See also references of EP 0679087A1

Cited By (14)

    Publication numberPublication dateAssigneeTitle
    US-7494643-B2February 24, 2009Rendon Marta IMethod and topical composition for the treatment of hyperpigmented skin
    US-7645860-B2January 12, 2010Baxter Healthcare S.A., Baxter International Inc.Factor VIII polymer conjugates
    US-7982010-B2July 19, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-7985838-B2July 26, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-7985839-B2July 26, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8003760-B2August 23, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8053561-B2November 08, 2011Baxter International Inc., Baxter Healthcare S.A.Pegylated factor VIII
    US-8067543-B2November 29, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8071724-B2December 06, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8071725-B2December 06, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8071726-B2December 06, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8071727-B2December 06, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8071728-B2December 06, 2011Baxter International Inc., Baxter Healthcare S.A.Factor VIII polymer conjugates
    US-8637007-B2January 28, 2014Baxter International Inc., Baxter Healthcare SaFactor VIIa-polysialic acid conjugate having prolonged in vivo half-life